Gland Pharma Limited (GLAND.NS)
- Previous Close
1,415.60 - Open
1,400.00 - Bid --
- Ask --
- Day's Range
1,384.40 - 1,428.50 - 52 Week Range
1,277.80 - 2,220.95 - Volume
91,064 - Avg. Volume
325,163 - Market Cap (intraday)
234.942B - Beta (5Y Monthly) 0.27
- PE Ratio (TTM)
33.36 - EPS (TTM)
42.75 - Earnings Date May 20, 2025
- Forward Dividend & Yield 20.00 (1.41%)
- Ex-Dividend Date Aug 16, 2024
- 1y Target Est
1,712.91
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastrointestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain and analgesics, respiratory, and vitamins, minerals, and nutrients; and contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
www.glandpharma.com4,217
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: GLAND.NS
View MorePerformance Overview: GLAND.NS
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLAND.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLAND.NS
View MoreValuation Measures
Market Cap
233.23B
Enterprise Value
207.19B
Trailing P/E
33.11
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.09
Price/Book (mrq)
2.65
Enterprise Value/Revenue
3.63
Enterprise Value/EBITDA
13.93
Financial Highlights
Profitability and Income Statement
Profit Margin
12.30%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
57.29B
Net Income Avi to Common (ttm)
7.04B
Diluted EPS (ttm)
42.75
Balance Sheet and Cash Flow
Total Cash (mrq)
28.2B
Total Debt/Equity (mrq)
3.72%
Levered Free Cash Flow (ttm)
--